{
    "2021-02-09": [
        [
            {
                "time": "",
                "original_text": "智飞生物：持股1.83%的股东吴冠江减持1.44% 减持股份",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "吴冠江",
                        "减持",
                        "1.44%",
                        "股份"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "智飞生物(300122.SZ)：持股5%以上股东吴冠江减持1.44%股份 减持股份",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "吴冠江",
                        "减持",
                        "1.44%",
                        "股份"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "智飞生物(300122.SZ)遭主要股东吴冠江减持2296.82万股 减持比例超1% 减持股份",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "吴冠江",
                        "减持",
                        "2296.82万股",
                        "1%"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "智飞生物：吴冠江减持1.44%公司股份 减持股份",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "吴冠江",
                        "减持",
                        "1.44%",
                        "股份"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "医药行业一周观察：疫情或转为持久战 行业景气度提升",
                "features": {
                    "keywords": [
                        "医药行业",
                        "疫情",
                        "持久战",
                        "景气度提升"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "2020MNC中国区业绩大比拼：默沙东升档、赛诺菲新品青黄不接",
                "features": {
                    "keywords": [
                        "2020MNC",
                        "中国区",
                        "默沙东",
                        "赛诺菲",
                        "新品",
                        "青黄不接"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "2020年疫苗批签发报告：核心品种整体批签发大幅增长 肺炎、HPV、流感等疫苗表现强劲",
                "features": {
                    "keywords": [
                        "2020年",
                        "疫苗",
                        "批签发",
                        "核心品种",
                        "肺炎",
                        "HPV",
                        "流感",
                        "增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}